LIPI Keynote Address Damian Hine final (NXPowerLite)

Experience in the Implementation of
Innovation and Commercialisation
LIPI Technopreneurship and Technology Transfer National Seminar
12th November 2015.

Associate Professor Damian Hine
UQ Business School

Ideas?

These are all patented, but this is NOT what we do.

UQ Successes
Over 30 years of technology transfer at UQ.
Up to 500 invention disclosures a year.
Some Successes:
Gardasil

- sales over $10Bn

Spinifex Pharmaceuticals


- Investment of $1Bn

Triple P (Positive Parenting Program)
TetraQ
Impedimed
Leximancer

- in over 30 countries

- servicing mostly US and Japanese clients
- Market capitalization $254M
- global leader in text analytics

We don’t just do it – we teach it

• Many universities undertake technology
transfer and research commercialisation.
• Few have been successful in integrating it
in to their programs.

• We have integrated commercialisation in
to undergraduate, postgraduate
coursework, and PhD programs

Where have we taken our success?
• Lean LaunchPad – National program for CSIRO

• International programs – Vietnam, Chile,
Panama, Ecuador, Brazil

• Embedded in our teaching programs – Graduate
Certificate in Research Commercialisation; Master
of Technology Innovation Management – you can
only run these programs successfully if you are
already research intensive.

We must remember –
Researchers are not Entrepreneurs
Private


Entrepreneurs

Funding source

Inventors

Innovators

Researchers

Public
Technology
Push

Market Pull

Innovation driver

Researchers are usually doing problem solving science. They will rarely ever meet a final
customer/user/patient.

Innovators can combine the elements of each of the others – but are VERY RARE.

Whe resear hers do dis o er so ethi g…
What do I
do with it?

Who will
use it?

It is commercially
viable?

I discover
something
What’s next?

How do I get
out of it?

Does viability

matter?

Helping
researchers by
lighting a pathway

Do I expand it?

How do I
protect it?
Do I develop
it?

How do I
fund it?
How much will
development cost?

Do I protect it?


How do I
develop it?
How long will
it take?

Who will
help me?

CRICOS Provider Number 00025B

The Twelve Steps
1.
2.
3.
4.
5.
6.
7.
8.
9.

10.
11.
12.

Public/private good discussion – decision on mix
Commercial viability or non-commercial value – societal, spiritual, justice, QoL value
Types of IP – it would be very rare that it is unique – fit for purpose
IPRs and Protection types or not - Level of disclosure, cost and complexity, what
requirements of each type of IP does it meet
Who owns the IP – where do you sit, what contractual arrangements are or should be in
place?
Advice and support – pate t attor eys, la yers, te h i al support, fi a ial…
Market/audience $ and or size, growth, penetration. Not just macro-market, but your actual
market.
Competitors and/or collaborators – know the cauldron are you entering.
Pathways – compare possible alternatives and decide – start-up, license, JV, SA, spin-off…
Development cycle – how long, how much, how hard, how complex
Horizons – one to three - looking in to the future for disruptions
Supporting financials – including valuation, funding, cost of protection, market revenues.


Public/private
good –
decision on
mix

Where does your idea/technology sit?
One of the best ways to define the
commercial (or non-commercial) viability of
a technology is to assess its excludability
and its rivalry.

FOUR TYPES OF GOODS
Rival?
Low

High

Private Goods
High


Excludable?

Low

Collective Good

Full cost
vaccines
in to US,
Europe

Free
vaccines
in to
Myanmar
Common Goods
?

Low cost
vaccines

in to
Myanmar
Public Goods

Rivalry - Does o e perso ’s use of the good di i ish a other perso ’s a ility to use it?
Excludability - Can people be prevented from using the good?
Demand side and supply side can see things differently.

You can indicate single or multiple
sites and sizes.
Rival?
Low

High

Collective Good
High

Private Goods
Time

3

Excludable?
Common Goods

Low
Time
1

Time
2

Public Goods

Commercial
viability or
noncommercial
value

Societal
Value

Public Good

Viability - What type of value dominates?
Commercial
Value

Private Good

Low excludability

High excludability

Low rivalry

High rivalry

De-risking the venture is essential,
but needs time and progress.
Value

$$
You want
to be are
here

You
are
here

Risk

or
here

Proof of
Principle

Proof of
Concept

Working
prototype

Manufacturing
prototype

Market launch

Moving up through the
Technology Readiness Levels

You
want to
be here
How
long
will it
take?
You
are
here

Questions to ask yourself:
Where are you now
(viability)?
How far do you want to take it
yourself (Exit strategy)?
By when (Devt Cycle)?
With whom (Collaborators)?
With whose help (Advice and
Support)?
What will it cost (Financials)?
What’s next Horizons ?

Who owns the
IP – where do
you sit,
contractual
arrangements in
place?

UQ – Who Owns it?
9. Reward for Staff Contributors

9.1 The University wishes to encourage innovation by rewarding staff,
students and visitors who create valuable IP ("contributors"), regardless of
whether that IP vests in research or teaching materials. The University will
ensure that the Net Proceeds of Commercialisation are distributed with

one-third to the contributors, one-third to the relevant
Faculty/Institute and one-third to central University funds.
"Net Proceeds of Commercialisation" means the total of net cash revenues
received from commercialising the IP (including royalties, license fees,
milestone payments, dividends and proceeds from the sale of shares but
excluding R&D funds, consulting funds, returns from direct investment by
the University or a Commercial Company, and any encumbered revenues
until the encumbrance is lifted). Net Proceeds of Commercialisation are less
all expenses incurred by or on behalf of the University in respect of
commercialising the technology that have not previously been recovered.

Advice and
support –
patent attorneys,
lawyers,
technical,
financial…

Venture Capital
Government Agency
R&D Funding Agency

Discovery

Proof of
Concept

R&d

Scale-up

Manufacturing
Prototype

Research Centre

Research Institute
Research Organisation

R&D Consortium
Research Facility
Commercialisation/Translational Organisation
Commercial Law
Management and Financial Consultancy

Market
Launch

Market/audience
$, size, growth,
penetration. Macro
to micro markets.

Be realistic and know your market
(everyone, everywhere, now and in the future)

Macro Market –
global market in yours and
related fields – “This is a
$10Bn market”.

Meso Market –
National market, or those
in your specific field –
“This is a $590M market”

Micro Market – local
market, or those directly
competing in your chosen field
– “This is a $90M market”

Development
cycle – how
long, how much,
how hard, how
complex

Realistic timelines

Competitors
and/or
collaborators

Compared with the competition?
How do you propose to get there?
How long will it take?
Who else is on the same path?
Are they ahead of you or behind you?
What will kill your value?

Value

Competitor
4

$$

De-risking
Competitor
3

Competitor
1

Competitor
2

Risk

Your
idea/tech

Proof of
Principle

Proof of
Concept

Working
prototype

Manufacturing
prototype

Market launch

Knowing the competitive landscape

Size of firms

License to a
Licence?
Other options
to firm?
mid-tier
consider that are more
relevant to your
industry and technology
JV?
Start-up?

Number of firms

• Large number of smaller players  points to a start-up
• Small number of larger players  points to a licence
• Also informs exit...

Pathways and partnering –
UQ and UniQuest

Pathways –
compare as
many possible
alternatives
before deciding

Research Catchment

Hub

Plan Selection and Strategy
8. Start-up

6. Full Screen

9. Investment

5. 1st Cut

8.Product/
Service

9. Clients

1.Research 7. IP Protection
2. Discovery

3.Disclosure

4.PDD
Exit point – not
commercially viable

Exit Strategy
M&A,
Trade
Sale

StartUp
License

8.License

9. Partnership

Royalty
Annuity

SKILLS
EDUCATION

Technology
Valuation

Business Model
Negotiation

Partnering
Planning

Structures
Governance

IP Management Commercialisation in
Practice

UniQuest Internship

Commercialisation
Workshop

Research Catchment

Hub

Analysis
IP Strategy

Plan Selection and Strategy

9. Investment

5. 1st Cut
MICD, GM,
Researches

8. Start-up

6. Full Screen

CSIRO Internship

Analysts, Lawyer,
Patent Attorney,
Project Team

Experience
required

7. IP Protection

2. Discovery
Comm Mgr
UniQuest

3.Disclosure

1.Research

IP Protection
Project Mgmt

4.PDD
Analysts,
UniQuest
Internships

8.Product/
Service
iLab Internship
AIC Internship

UniSeed, Angels,
iLab Incubator, VCs,
Industry, Enterprize

Legal
Pitching/Sale

Exit Strategy

M&A,
Trade Sale
Start-up
License

9. Clients
C&R,
International
Projects, UQBS
Commercialisation

Royalty
Annuity

9. Partnership
Industry

8.License

Patent Review
Committee, Lawyer,
Patent Attorney,
Researchers

Commercialisation
in Practice

UQ

Comm Manager,
UniQuest,

Exit point

INTERNAL PARTNERS

UQ Business School - Grad School - UniQuest - JK Tech - - UniSeed - iLab

EXTERNAL PARTNERS Angel Network - Enterprise Connect - Accelerating Commercialisation–CSIRO – BTP – Lawyers– Patent Attorneys - Companies

Partners

Successful
ideas

Horizons –

one to three –
the future is
now.

The Three Horizons Model –
planning your technology trajectory
The Alchemy of Growth, Baghai,
Coley & White

Horizon 1:


Your current technology position

Horizon 2:


Leveraging your current technology
to build your second generation
technology

Horizon 3:


The unexpected future – where will
disruptions come from?

Your technology position may
change across horizons.
Rival?
Low

High

Collective Good
High

Private Goods
Second
tech

Excludable?
Common Goods

Low
Main
technology

Third
tech

Public Goods

Supporting
financials and
exit strategy

Financials
They reflect every other area
They help get finance and investment funding

Bringing it all together
Two stage iteration
1st
1st

1st

2nd

1st

2nd

2nd

1st
2nd

2nd

1st

2nd

1st

2nd

2nd

2nd
1st

1st

2nd

2nd
2nd

1st

1st
1st

CRICOS Provider Number 00025B

Bringing it all together
An Example